Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 2/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392980 | 0.95 | SMN1; SMN2 (0.83) | USP2SMN1; SMN2MEN1KMT2ATP53 | |
| SCHEMBL2920417 | 0.88 | SMN1; SMN2 (0.83) | USP2SMN1; SMN2MEN1KMT2ATP53 | |
| SCHEMBL344191 | 0.88 | SMN1; SMN2 (0.96) | USP2SMN1; SMN2TP53RECQLHPGD | |
| SCHEMBL18084793 | 0.87 | SMN1; SMN2 (0.80) | USP2SMN1; SMN2MEN1KMT2ATP53 | |
| SCHEMBL26129549 | 0.86 | HPGD (0.60) | USP2SMN1; SMN2MEN1KMT2ARECQL | |
| SCHEMBL20448044 | 0.86 | SMN1; SMN2 (1.00) | USP2SMN1; SMN2TP53RECQLHPGD | |
| SCHEMBL24762569 | 0.86 | USP2 (0.73) | USP2SMN1; SMN2MEN1KMT2ATP53 | |
| SCHEMBL26130219 | 0.84 | HPGD (0.63) | USP2SMN1; SMN2MEN1KMT2AHPGD | |
| SCHEMBL12629406 | 0.84 | USP2 (0.76) | USP2SMN1; SMN2MEN1KMT2ARECQL | |
| SCHEMBL16612394 | 0.84 | USP2 (0.62) | USP2SMN1; SMN2MEN1KMT2ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| EP-2215080-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | Boehringer Ingelheim International GmbH (DE) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009055357-A1 | DIAZEPANE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | WO | disclosed |
| US-6750214-B2 | PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | COLLIS ALAN JOHN (US) | 2004-06-15 | — | — | US | disclosed |
| US-20040034032-A1 | Quinoline and quinazoline compounds useful in therapy | PFIZER INC | 2004-02-19 | — | — | US | disclosed |
| EP-0887344-B1 | Quinolines and quinazolines useful in therapy | PFIZER LTD (GB) | 2003-12-03 | — | — | EP | disclosed |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. | 2003-11-27 | — | — | US | disclosed |
| US-6653302-B2 | Benign prostatic hyperplasia | PFIZER INC. | 2003-11-25 | — | — | US | disclosed |
| US-6649620-B2 | Particularly in the treatment of benign prostatic hyperplasia. | PFIZER INC. | 2003-11-18 | — | — | US | disclosed |
| US-6642242-B2 | Antiproliferative agents to treat benign prostatic hyperplasia | PFIZER INC. | 2003-11-04 | — | — | US | disclosed |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2002-04-04 | — | — | US | disclosed |
| US-6365599-B1 | FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA | PFIZER, INC. | 2002-04-02 | — | — | US | disclosed |
| US-6169093-B1 | FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER INC. | 2001-01-02 | — | — | US | disclosed |
| US-6103738-A | Quinoline and quinazoline compounds useful in therapy | PFIZER INC. (US) | 2000-08-15 | — | — | US | disclosed |
| EP-0877734-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER RES & DEV (IE) | 2000-07-12 | — | — | EP | disclosed |
| US-6048864-A | Quinolines and quinazolines useful in therapy | PFIZER INC (US) | 2000-04-11 | — | — | US | disclosed |
| EP-0968208-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | Pfizer Limited (GB) | 2000-01-05 | — | — | EP | disclosed |
| EP-0887344-A1 | Quinolines and quinazolines useful in therapy | Pfizer Limited (GB) | 1998-12-30 | — | — | EP | disclosed |
| EP-0875506-A1 | Quinoline and quinazoline compounds useful in therapy | Pfizer Limited (GB) | 1998-11-04 | — | — | EP | disclosed |
| WO-1998030560-A1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BEGNIN PROSTATIC HYPERPLASIA | PFIZER LIMITED (GB) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | BPHL, LPXN, NQO2 | USP2 3275/4885SMN1; SMN2 3990/4885MEN1 92/4885 |
| US-20100261708-A1 | Diazepane Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, BDKRB2 | USP2 4176/4885SMN1; SMN2 4612/4885MEN1 4504/4885 |
| US-20040034032-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, LPXN, SDHA | USP2 3480/4885SMN1; SMN2 3191/4885MEN1 300/4885 |
| US-20030220332-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, ADRB3 | USP2 3351/4885SMN1; SMN2 3839/4885MEN1 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.